- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01299285
Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects
May 15, 2017 updated by: Eli Lilly and Company
Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Male Subjects
This is a single dose study of radiolabeled [14C]-LY3009104 in healthy male volunteers to study the absorption, distribution, metabolism, and elimination of LY3009104.
This study requires minimum of 7 days and maximum of 22 days stay.
This study is for research purposes only and is not intended to treat any medical condition.
Study Overview
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Overtly healthy males, as determined by medical history and physical examination
- Will either be sterile or, if sexually active, agree to use a reliable method of birth control from check-in until 3 months after the end of the study
- Body mass index (BMI) between 19 and 30 kilogram/square meter (kg/m²)
- Experience on average 1 to 2 bowel movements per day
- Clinical laboratory test results within the normal reference range for the clinical research unit (CRU) or, results with acceptable deviations which are judged to be not clinically significant by the investigator
- Normal blood pressure and heart rate (sitting) as determined by the investigator
- Venous access sufficient to allow blood sampling
- Are reliable and willing to make themselves available for the duration of the study, and are willing to abide by the CRU policies and procedures, and study restrictions
- Have given written informed consent approved by Lilly and the Institutional Review Board (IRB) governing the CRU
Exclusion Criteria:
- Are currently enrolled in, have completed or discontinued, a clinical trial involving an investigational product or are concurrently enrolled in any other type of medical research judged not to be scientifically, or medically compatible with this study
- Have known allergies to LY3009104, related compounds, or any components of the formulation
- Have previously received the investigational product in this study, have completed or withdrawn from this study or any other study investigating LY3009104
- History or presence of an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, is clinically significant
- Current or recent history (<30 days prior to Screening and/or <45 days prior to Check-in) of a clinically significant bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection
- An Absolute Neutrophil Count (ANC) less than 2000 cells/microliter. For abnormal values a single repeat will be allowed
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
- Show evidence of significant active neuropsychiatric disease and in particular evidence of significant medical or psychiatric illness within the past 12 months
- Have known substance dependence or abuse within 6 months prior to the study (according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV] diagnosis), or regularly use known drugs of abuse and/or show positive findings on urinary drug screening
- Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
- Show evidence of hepatitis C and/or positive hepatitis C antibody
- Evidence hepatitis B (active or surface antigen positive [HBsAg+]) or hepatitis B core antibody positive, hepatitis B surface antibody negative (HBcAb+, HBsAb-)
- Use of prescription medication; over-the-counter medication; or herbal preparations containing St. John's Wort, kava, garlic, ginger, gingko biloba, or guarana within 14 days prior to admission
- Consumption of grapefruit or grapefruit-containing foods or juices within 7 days prior to dosing or at any time during the study
- Have an average weekly alcohol intake that exceeds 15 units per week, or are unwilling to stop alcohol consumption for the duration of the study (1 unit = 12 oz or 360 milliliter (mL) of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
- Consume 5 or more cups of coffee (or other beverages of comparable caffeine content) per day, on a habitual basis, or any subjects unwilling to adhere to study caffeine restrictions (no caffeine 48 hours prior to admission until the end of study
- Use of tobacco or nicotine-replacement products within the 6 months prior to study entry or at any time during the study
- Have donated blood of more than 500 mL within the last month
- Have participated in a 14C-study within the last 6 months prior to Check-in for this study. The total exposure from this study and the previous study must be within the Code of Federal Regulations (CFR) recommended levels considered safe (per 21 CFR 361.1), for example less than 5,000 millirem (mrem)/year whole body annual exposure
- Exposure to significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LY3009104
Single 10-milligram (mg) oral dose containing 100 microcuries of 14C-labeled LY3009104
|
Administered orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of the Total Radioactive Dose Administered Excreted From Urine and Feces
Time Frame: Baseline up to 120 hours
|
Baseline up to 120 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Pharmacokinetics: LY3009104 Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]
Time Frame: Baseline up to 48 hours
|
Baseline up to 48 hours
|
|
Plasma Pharmacokinetics: Radioactivity Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]
Time Frame: Baseline up to 48 hours
|
Baseline up to 48 hours
|
|
Plasma Pharmacokinetics: Maximum Observed LY3009104 Concentration (Cmax)
Time Frame: Baseline up to 48 hours
|
Baseline up to 48 hours
|
|
Plasma Pharmacokinetics: Maximum Observed Radioactivity Concentration (Cmax)
Time Frame: Baseline up to 48 hours
|
Baseline up to 48 hours
|
|
Plasma Pharmacokinetics: LY3009104 and Radioactivity Time to Maximum Observed Concentration (Tmax)
Time Frame: Baseline up to 48 hours
|
Baseline up to 48 hours
|
|
Percentage of Dose of LY3009104 and LY3009104 Metabolites in Urine
Time Frame: Baseline up to 48 hours
|
Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the urine are reported.
Only those metabolites that were detectable in the urine are included in the report.
|
Baseline up to 48 hours
|
Percentage of Dose of LY3009104 and LY3009104 Metabolites in Feces
Time Frame: Baseline up to 72 hours
|
Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the feces are reported.
Only those metabolites that were detectable in the feces are included in the report.
|
Baseline up to 72 hours
|
Percentage of Total Radioactivity of LY3009104 and LY3009104 Metabolites in Plasma
Time Frame: Baseline up to 24 hours
|
Baseline up to 24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559, Mon - Fri, 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2011
Primary Completion (Actual)
March 1, 2011
Study Completion (Actual)
March 1, 2011
Study Registration Dates
First Submitted
February 16, 2011
First Submitted That Met QC Criteria
February 16, 2011
First Posted (Estimate)
February 18, 2011
Study Record Updates
Last Update Posted (Actual)
June 8, 2017
Last Update Submitted That Met QC Criteria
May 15, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 14010
- I4V-MC-JADG (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on LY3009104
-
Eli Lilly and CompanyIncyte CorporationTerminatedSystemic Lupus ErythematosusUnited States, China, France, Czechia, Taiwan, Hungary, Belgium, Australia, Korea, Republic of, Serbia, Mexico, Poland, Italy, United Kingdom, Germany, Spain, Japan, South Africa, Austria, Russian Federation, Israel, India, Argentina, Croati... and more
-
Eli Lilly and CompanyCompletedJuvenile Idiopathic ArthritisSpain, India, Israel, Japan, Australia, Belgium, Turkey, Mexico, Italy, Germany, Czechia, United Kingdom, China, Russian Federation, Poland, Brazil, France, Austria, Argentina, Denmark
-
Eli Lilly and CompanyIncyte CorporationCompletedAtopic DermatitisFrance, India, Germany, Japan, Italy, Czechia, Mexico, Taiwan, Russian Federation, Denmark
-
Aaron R. MangoldCompletedCutaneous Lichen PlanusUnited States
-
Eli Lilly and CompanyNo longer availableChronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE) | Juvenile Dermatomyositis (JDM) | Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI) | Aicardi-Goutières Syndrome (AGS)United States, United Kingdom
-
Eli Lilly and CompanyCompletedHealthy VolunteersUnited Kingdom
-
Eli Lilly and CompanyIncyte CorporationCompletedArthritis, Rheumatoid | Chronic Inflammatory DisorderSingapore
-
Eli Lilly and CompanyRecruitingCovid19 | Corona Virus InfectionUnited States, Spain, Mexico, Belgium, Brazil
-
Eli Lilly and CompanyRecruitingJuvenile Idiopathic ArthritisBelgium, Spain, Australia, India, Japan, Italy, Czechia, Germany, Austria, France, United Kingdom, China, Mexico, Israel, Brazil, Denmark, Poland, Russian Federation, Argentina, Turkey
-
Eli Lilly and CompanyActive, not recruitingAicardi Goutieres Syndrome | Nakajo-Nishimura Syndrome | Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome | STING-Associated Vasculopathy With Onset in InfancyJapan